Kamada Ltd.

Alpha-1 Antitrypsin Deficiency

Kamada Ltd. is engaged in clinical research for adults with congenital alpha-1 antitrypsin deficiency, with attention to patients who have moderate to severe airflow limitation and reduced pulmonary function.

  • Congenital alpha-1 antitrypsin deficiency
  • Adult respiratory disease
  • Pulmonary function impairment

The sponsor’s research focus in this area centers on chronic lung disease associated with inherited protein deficiency.

Chronic Obstructive Pulmonary Disease

The clinical programme also addresses COPD-related airway limitation in a population selected for stable disease without frequent recent exacerbations, reflecting interest in long-term respiratory management.

  • Airflow limitation
  • Bronchodilator response
  • Chronic respiratory impairment

This area aligns with therapeutic development for persistent obstructive pulmonary conditions.

Inhalation Therapy

Kamada Ltd. is active in research involving inhaled therapy for respiratory disease, with an emphasis on targeted delivery to the airways and maintenance treatment over an extended period.

  • Inhaled protein replacement
  • Airway-targeted treatment
  • Long-term respiratory therapy

The company’s therapeutic interest includes treatments designed for chronic administration in pulmonary medicine.

Respiratory Function Assessment

Its research landscape includes clinical evaluation of lung function in patients with inherited respiratory disease, with attention to measures of expiratory performance and airway obstruction.

  • FEV1
  • Forced expiratory assessment
  • Airflow mechanics

This reflects a strong interest in objective respiratory endpoints relevant to chronic obstructive disease management.

Multicenter Respiratory Research

The sponsor supports multicenter clinical research across several countries, indicating activity in internationally coordinated studies focused on rare respiratory disorders.

  • International study networks
  • Rare disease research
  • Specialist pulmonary sites

Its clinical interests are concentrated in specialty respiratory care for inherited and chronic obstructive lung disease.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Study of inhaled alpha1-proteinase inhibitor (Kamada-AAT) in adults with alpha-1 antitrypsin deficiency and moderate to severe airflow limitation

    Not recruiting

    3 1
    Belgium Finland Ireland The Netherlands Sweden